After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, IMVT falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Immunovant Inc is $2.56B. A total of 0.81 million shares were traded on the day, compared to an average of 1.30M shares.
In the most recent transaction, Stout Jay S sold 2,805 shares of IMVT for 18.15 per share on Jul 23 ’25. After the transaction, the Chief Technology Officer now owns 204,919 company shares. In a previous transaction on Jul 23 ’25, Geffner Michael sold 2,385 shares at 18.15 per share. IMVT shares that Chief Medical Officer owns now total 221,825.
Among the insiders who sold shares, Geffner Michael disposed of 1,160 shares on Jul 09 ’25 at a per-share price of $17.24. This resulted in the Chief Medical Officer holding 224,210 shares of IMVT after the transaction. In another insider transaction, Stout Jay S sold 1,519 shares at $17.24 per share on Jul 09 ’25. Company shares held by the Chief Technology Officer now total 207,724.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, IMVT has a high of $34.47 and a low of $12.72.
As of this writing, IMVT has an earnings estimate of -$0.72 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.74 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. IMVT’s latest balance sheet shows that the firm has $493.82M in Cash & Short Term Investments as of fiscal 2022. There were $2.36M in debt and $44.52M in liabilities at the time. Its Book Value Per Share was $3.56, while its Total Shareholder’s Equity was $469.82M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMVT is Buy with a score of 4.41.
